EMA drafts 16 product-specific guidelines for more consistent BE testing
This article was originally published in SRA
Executive Summary
Generic drug companies wanting to develop products containing any of 16 pharmaceutical substances should have a clearer idea of how to go about doing so, after the European Medicines Agency released a set of draft product-specific guidelines on demonstrating bioequivalence1.